Ergoferon, pills for dissolution, 20pcs

Product description

Ergoferon-has several therapeutic effects. The first and most important thing is the antiviral effect. The second equally important effect of the drug is immunomodulatory. The drug mobilizes the body’s defenses for a more coordinated and rapid fight against infection, including through active recognition of the pathogen and an adequate immune response to its invasion. Due to its anti-inflammatory and antihistamine effects, Ergoferon helps reduce the severity and duration of mucosal edema, bronchospasm and cough. The drug Ergoferon is available in a convenient dosage form (tablets for resorption) and can be used to treat influenza and ARVI in all family members-adults and children starting from 6 months of age.

Composition

For 1 tablet: Active ingredients: antibodies to human gamma interferon affinity purified – 0.006 g*, antibodies to histamine affinity purified – 0.006 g*, antibodies to CD4 affinity purified – 0.006 g*Excipients: lactose monohydrate 0.267 g, microcrystalline cellulose 0.03 g, magnesium stearate 0.003 g* are applied to lactose monohydrate in the form of a mixture of three active water-alcohol dilutions of the substance, diluted respectively in 100 ml,100 30,100 50 times.

Pharmacological action

The spectrum of pharmacological activity of Ergoferon includes antiviral, immunomodulatory, antihistamine, anti-inflammatory. The effectiveness of the use of Ergoferon components in viral infectious diseases has been experimentally and clinically proven: influenza A and influenza B, acute respiratory viral infections (caused by parainfluenza viruses, adenoviruses, respiratory syncytial viruses, coronaviruses), herpesvirus infections (labial herpes, ophthalmic herpes, genital herpes, herpes zoster, chickenpox, infectious mononucleosis), acute intestinal infections infections of viral etiology (caused by caliciviruses, coronaviruses, rotaviruses, enteroviruses), enterovirus and meningococcal meningitis, hemorrhagic fever with renal syndrome, tick-borne encephalitis. Ergoferon is used in the complex therapy of bacterial infections (pseudotuberculosis, whooping cough, yersiniosis, pneumonia of various etiologies, including atypical pathogens (M. pneumoniae, C. Pneumoniae, Legionella spp. ), is used to prevent bacterial complications of viral infections, and prevents the development of superinfections. The use of Ergoferon in the pre-and post-vaccination period increases the effectiveness of vaccination, provides non-specific prevention of acute respiratory viral infections and influenza at the time of the formation of post-vaccination immunity. Ergoferon has a preventive effectiveness against acute respiratory viral infections of non-influenza etiology, prevents the development of intercurrent diseases in the post-vaccination period. The components included in the preparation Ergoferon have a single mechanism of action in the form of an increase in the functional activity of the CD4 receptor, interferon gamma (IFN-gamma) and histamine receptors, respectively; this is accompanied by a pronounced immunotropic effect. It has been experimentally proven that antibodies to interferon gamma: they increase the expression of IFN-γ, IFN α/β, as well as interleukins associated with them (IL-2, IL-4, IL-10, etc. ), improve the ligand-receptor interaction of IFN, restore cytokine status; normalize the concentration and functional activity of natural antibodies to IFN-γ, which are an important factor in the body’s natural antiviral tolerance; stimulate interferon-dependent biological processes: induction of the expression of antigens of the main histocompatibility complex types I, II and Fc receptors, activation of monocytes, stimulation of the functional activity of NK cells, regulation of the synthesis of immunoglobulins, activating a mixed Th1 and Th2 immune response. Antibodies to CD4, probably being allosteric modulators of this receptor, regulate the functional activity of the CD4 receptor, which leads to an increase in the functional activity of CD4 lymphocytes, normalization of the CD4/CD8 immunoregulatory index, as well as the subpopulation composition of immune-competent cells (CD3, CD4, CD8, CD16, CD20). Histamine antibodies modify the histamine-dependent activation of peripheral and central H1 receptors and thus reduce the tone of bronchial smooth muscles, reduce capillary permeability, which leads to a reduction in the duration and severity of rhinorrhea, nasal mucosa edema, coughing and sneezing, as well as a decrease in the severity of allergic reactions associated with the infectious process due to suppression of histamine release from mast cells and basophils, leukotriene production, and reduced eosinophil chemotaxis and platelet aggregation in reactions to allergen contact. The combined use of the components of the complex drug Ergoferon is accompanied by an increase in the antiviral activity of its components.

Indications

Ergoferon is indicated for use in adults and children over the age of 6 months. Treatment of influenza and acute respiratory viral infections (ARVI). Treatment of acute intestinal infections of viral etiology.

Use during pregnancy and lactation

The safety of using Ergoferon in pregnant women has not been studied. During pregnancy and lactation, the drug is used only if the intended benefit to the mother exceeds the potential risk to the fetus and child. The benefit-risk ratio is determined by the attending physician. If necessary, the drug can be combined with other antiviral and symptomatic agents.

Contraindications

Increased individual sensitivity to the components of the drug. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Children under 6 months of age.

Side effects

Possible reactions of increased individual sensitivity to the components of the drug.

Interaction

No cases of incompatibility with other medicinal products have been reported so far.

How to take, course of use and dosage

It is not intended to divide the tablet into parts. Inside, not during meals. The tablet should be kept in the mouth, not swallowed, until completely dissolved. When prescribing the drug to young children (from 6 months to 3 years), it is recommended to dissolve the tablet in a small amount (1 tablespoon) of boiled water at room temperature. Adults and children from 6 months of age. On the 1st day of treatment, take 8 tablets according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day until complete recovery.

Overdose

In case of accidental overdose, dyspeptic phenomena due to the fillers included in the preparation are possible.

Description

Tablets are flat-cylindrical in shape with a risk and chamfer, from white to almost white in color. On the flat side with a risk, the inscription MATERIA MEDICA is applied, on the other flat side, the inscription ERGOFERON is applied.

Special instructions

The drug contains lactose monohydrate, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or with congenital lactase deficiency.

Form of production

Tablets for resorption. 20 tablets each in a contour cell pack made of polyvinyl chloride film and aluminum foil. 1,2 or 5 contour cell packages together with instructions for medical use are placed in a pack of cardboard.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C. Keep out of reach of children.

Shelf

life is 3 years.

Do not use after the expiration date.

Active ingredient

Antibodies

Dosage form

tablets for resorption

Description

Pregnant women as prescribed by a doctor, For adults, Children over 6 months, Nursing mothers as prescribed by a doctor

Indications

Flu, Flu and Cold Prevention, Colds, Whooping Cough, Herpes